Ignite Creation Date:
2024-05-06 @ 3:20 PM
Last Modification Date:
2024-10-26 @ 1:48 PM
Study NCT ID:
NCT04603976
Status:
UNKNOWN
Last Update Posted:
2020-10-27
First Post:
2020-10-07
Brief Title:
Registry for Migraine - Clinical Core
Sponsor:
Danish Headache Center
Organization:
Danish Headache Center
Study Overview
Official Title:
Registry for Migraine - Clinical Core
Status:
UNKNOWN
Status Verified Date:
2020-10
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
REFORM
Brief Summary:
This study aims to investigate the effect of erenumab on efficacy outcomes tolerability outcomes and patient-reported outcomes in individuals with migraine Furthermore the study aims to identify clinical predictors of erenumab response
Detailed Description:
Migraine is a prevalent neurological disorder and a leading cause of years lived with disability worldwide As of recent therapies targeting calcitonin gene-related peptide eg erenumab have been approved for the preventive treatment of migraine This study aims to investigate the effect of erenumab on efficacy outcomes tolerability outcomes and patient-reported outcomes in individuals with migraine Furthermore the study aims to identify clinical predictors of erenumab response
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None